Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives E-Book
57,45 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
This reference summarizes recent advancements in knowledge about cardiovascular disease and pharmacology. The goal of the book is to inform readers about recent findings on cardiovascular therapeutics and how to conduct experiments to evaluate natural products. It presents 10 chapters that cover basic clinical research on cardiovascular diseases and therapeutic agents derived from natural sources. The book concludes with a series of experiments that demonstrate the methods to test the ameliorative effects of 3 phytochemicals: Biochanin A (red clover), Zingiberene (ginger oil) and Betaine (sugar beet).
Key Features
- 10 chapters that highlight recent research cardiovascular medicine and pharmacology
- Covers knowledge about basic cardiovascular physiology, congestive heart failure treatment and the treatment of heart inflammation.
- Covers uses, benefits, and drawbacks of numerous rodent and non-rodent animal models for studying CVD
- Updates readers about 21st-century CRISPR-cas9 technology and its uses in CVD.
- Covers the significance of Indian Ayurvedic techniques on the cardiovascular system,
- Covers information about nutraceuticals for CVD therapy
- Includes experiments to evaluate 3 phytochemicals for the treatment of different heart diseases such as hypertension, obesity-cardiomyopathy and the mitigation of inflammatory cytokines in myocardial infarction.
This book is an informative resource for cardiologists, and researchers working in the field of cardiovascular pharmacology. It also helps readers to understand the benefits of herbal medications that are commonly available for consumption in homes.
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 367
Veröffentlichungsjahr: 2003
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
FOREWORD
I was delighted when I received a request from Dr. P. Brahmanaidu and Dr. V. V. Sathibabu Uddandrao to write a brief foreword to the reprint of this book because, for many years, I have admired their incredible contribution to research especially in the field of metabolic disorders and nutraceuticals. I was excited when they started writing a book on “Advancements in Cardiovascular Research and Therapeutics: Molecular and Nutraceutical Perspectives” and I would be first in line to buy it. In fact, editors sent me a copy of the book draft and I was humbled. Not only was this a great book, but it was also a great way to write and construct chapters.
Looking through this magnificent volume, I am absolutely amazed by the way they presented this book about the pathophysiology of cardiovascular disorders and their novel treatment approaches by nutraceuticals. It is more than a book of lovely illustrations and a mine of information, demonstrating therapeutic approaches and it is a source of inspiration and information in the field of cardiovascular pharmacology. This book is unique and surely a work of treasure for anyone who is interested in cardiovascular research. So, I strongly recommend you to read it, enjoy it and learn from it.
PREFACE
Cardiovascular diseases (CVD) belong to the most severe health problems and are considered the main cause of morbidity and mortality in modern society. CVDs consist of a broad spectrum of diseases, including atherosclerosis, hypertension, myocardial ischemia, cardiomyopathy, and heart failure. Risk factors for CVDs include hypertension, hyperlipidemia, obesity, diabetes mellitus, metabolic syndrome, and a sedentary lifestyle. Therapeutic effects against CVD have been demonstrated by several medicinal plants and nutraceuticals thus presenting new possibilities for the treatment of CVD risk. Evidence suggests that this approach is very promising. So, the aim of this book is to present an update on the most recent evidence related to the use of nutraceuticals in the context of the prevention and treatment of CVD.
Chapter 1 discusses CVD and nutraceuticals and the underlying mechanism and therapeutic biomarkers. The chapter presents the beneficial effects of nutraceuticals on the heart and also gives an insight into the bioinformatics approach to identify novel therapeutic biomarkers in order to update the practitioner's awareness of the use of nutraceuticals for CVD management. Chapter 2 provides detail about congestive heart failure and insight into pharmacotherapy. This chapter explains possible pharmaceutical approaches to treat congestive heart failure. Chapter 3 provides a review of diet, inflammation, and CVDs. The chapter reveals the role of diet in the prevention of vascular inflammation and the usefulness of antioxidants in preventing CVD. Chapter 4 represents the applications, advantages and disadvantages of various rodent and non-rodent animal models in the research on CVD especially while evaluating nutraceuticals’ effects against CVD. On the other hand, chapter 5 discusses the CRISPR-cas9 technologies in the 21st century and their applications in cardiovascular diseases.
Chapter 6 discloses the role of Indian Ayurvedic approaches to the cardiovascular system, etiopathogenesis, and therapeutic strategies. The chapter highlights the precipitants that attenuate Vyana Vayu and addresses curative measures to restore Vyana Vayu. Chapter 7 depicts nutraceuticals as potential agents to rescue the human race from CVD. The chapter point outs the current scenario of CVD, pathophysiology, therapeutic drugs available, the role of nutraceuticals in treating CVD, and their mode of action with a special emphasis on commonly used kitchen spices. Chapter 8 explains the therapeutic potential and mode of action of Biochanin-A, a natural compound predominantly found in soy, chickpea, peanuts, alfalfa sprouts, and red clover against hypertension in experimental rats. Chapter 9 concentrates on the ameliorative potential of Zingiberene, a monocyclic sesquiterpene that is the principal constituent of ginger (Zingiber officinale) against obesity and cardiomyopathy. Finally, chapter 10 presents the amelioration of myocardial infarction through the attenuation of pro-inflammatory cytokines and matrix metalloproteinase production by Betaine, a well-known nutraceutical widely occurring in plants, animals and rich dietary sources.
List of Contributors
Cardiovascular Diseases and Nutraceuticals: Underlying Mechanism and Therapeutic Biomarkers
Pallavi Saxena1,Vinod Kumar2,Noopur Khare3,Neeraj Pal4,Dibyabhaba Pradhan5,Pradeep K Chaturvedi2,Arun Kumar Jain1,Manoj Kumar6,V. V. Sathibabu Uddandrao7,Umesh Kumar8,*Abstract
Food and nutrients are essential for the body's regular functioning. They aid in the preservation of an individual's health and the reduction of the danger of certain diseases. As a result of the widespread recognition of this fact, a link was established between “nutrition and health,” and the term “nutraceuticals” was coined. Nutraceuticals are therapeutic foods that aid in maintaining well-being, enhancing health, regulating immunity, and preventing as well as curing certain diseases. Nutraceuticals might thus be thought of as one of the missing pieces in a person's overall health. More than any other illness, cardiovascular disease has numerous risk variables that are susceptible to nutraceutical treatment. It is critical to see nutraceuticals' ability to improve cardiovascular risk factors as a huge opportunity in the treatment of a disease that affects so many people. Nutraceuticals show promise in clinical treatment since they have the potential to minimize the risk of chemotherapy-related side effects while also lowering the overall cost of health care. In this study, an attempt was made to summarize some of the most recent research findings on garlic, omega-3 fatty acids, soy products, dietary fibers, vitamins, antioxidants, plant sterols,
flavonoids, prebiotics, and probiotics that have beneficial effects on the heart, as well as to provide insight into a bioinformatics approach to identify novel therapeutic biomarkers in order to keep practitioners up to date.
1. INTRODUCTION
1.1. Cardiovascular Disorders
The term “cardiovascular disorders” (CVD) or “heart disease” refers to a variety of illnesses that affect the heart and blood arteries [1]. Coronary artery disease, cerebrovascular disease, angina, heart attack, heart failure, dilated and hypertrophic cardiomyopathy, peripheral arterial disease, rheumatic heart disease, heart rhythm problems (arrhythmias), congenital heart defects, deep vein thrombosis, and pulmonary embolism are all diseases that fall under the heart disease umbrella. Electrocardiogram (ECG), Holter monitoring, Echocardiogram, Stress test, cardiac catheterization, cardiac computed tomography (CT) scan, and cardiac magnetic resonance imaging are commonly used to diagnose it (MRI) [2]. CVD has surpassed cancer as the top cause of mortality worldwide, and it is a major public health issue. Obesity, metabolic syndrome, atherosclerosis, hyperlipidemia, type 2 diabetes, hypertension, and lifestyle risk factors such as smoking, physical inactivity, and dietary factors are all common and growing in popularity across the world [3]. Reducing risk variables in the population, particularly blood pressure control and cholesterol reduction can have an influence on CVD mortality [4]. Hypertension is to blame for 45% of heart attacks and 51% of strokes, as well as 9.4 million CVD-related deaths throughout the world [5]. Despite significant advancements in medical care, the prognosis for CVD remains dismal, and identifying causes and new therapeutic methods remains a high priority [6].
1.2. Cardiovascular Diseases Burden: Global and National
Cardiovascular diseases (CVDs) are the leading cause of death worldwide and a significant contributor to poor quality of life [7]. CVD claimed the lives of 17.8 million people globally in 2017, resulting in 330 million years of life lost and another 35.6 million years of disability [8]. Heart attacks and strokes account for four out of every five CVD fatalities, with one-third of these deaths occurring before the age of 70 [9]. Furthermore, case fatality due to CVD appears to be
significantly greater in low-income nations than in middle- and high-income countries [10].
The burden of cardiovascular disease (CVD) in India is one of the highest in the world. Noncommunicable diseases (NCDs), including cardiovascular disease (CVD), are projected to account for 60% of all adult fatalities in India, with CVD accounting for approximately 26% of these deaths [11]. The yearly number of CVD fatalities in India is expected to increase from 2.26 million in 1990 to 4.77 million in 2050 (2020). The age-standardized CVD mortality rate in India is 272 per 100,000, which is higher than the global average of 235 per 100,000 [8]. Over the last 25 years, the incidence of CVD risk factors has been significantly increasing in India, particularly in metropolitan areas [12].
Coronary heart disease prevalence rates in India have varied from 1.6% to 7.4% in rural populations and from 1% to 13.2% in urban populations during the last several decades [13]. Ischemic heart disease (IHD) and stroke account for the bulk of CVD mortality in India (83%) [14]. The ratio of IHD to stroke mortality in India is significantly greater than the worldwide norm and equivalent to that in Western developed nations [15]. IHD and stroke account for more than a twentieth (21.1%) of all deaths and one-tenth of all years of life lost in India [16]. The Macroeconomic Commission for Health predicted that the number of IHD patients in India would increase from 36 million in 2005 to 62 million in 2015 (70% increase). In general, India's stroke incidence and stroke-related case fatality rates are greater than those of Western industrialised nations, but the rates among women are especially high. Haemorrhagic strokes are more prevalent in India than in the Western population, according to current neuroimaging research [17].
Hypertensive heart disease, among other cardiovascular diseases, is a serious problem in India, with 1.47 million fatalities in 2019, up 138%from 1990 [18]. Rheumatic heart disease (RHD) is a concern in many regions of India, with an estimated 88,674 fatalities (7 per 100,000 population) in 2010. Though, from 2000 to 2010, the Indian Council of Medical Research (ICMR) began community management and prevention of RHD using hospital-based passive monitoring and secondary prophylaxis as part of the Jai Vigyan Mission Mode Project [19]. At the national level, there is no systematic program for the prevention and control of RHD. However, following adopting an economic liberalization and globalization strategy in 2000, India's socioeconomic situation, improved living circumstances, and increased connectivity and access to health-care institutions are predicted to have resulted in a decrease in the burden of RHD [20]. According to estimates from the Global Burden of Disease research, atrial fibrillation and flutter contribute very little to the total CVD burden in India. Furthermore, other types of
CVDs, such as aortic aneurysms, peripheral vascular disease, and endocarditis, have a tiny proportionate death and morbidity impact [21].
Although CVD risk factors are widespread in India, there are significant variations across and within areas. Diabetes mellitus appears to be more frequent in India's southern states, whereas hypertension tends to be more prevalent in the north-eastern regions. This variability may be the cause of cultural variety (leading to variances in food preferences, cigarette use, and physical activity patterns) as well as differences in economic growth across and within Indian states [22]. In India, the relationship between socioeconomic position and CVD has been well investigated. CVD is no longer a wealthy man's illness, according to a recent large cohort research in Mumbai, which found that it affects the poor equally, with lower SES males having greater CVD mortality. Low SES was linked to a greater risk of having acute myocardial infarction in a case-control study. In a cross-sectional examination of cardiovascular risk factors in Jaipur, suboptimal social features such as poor educational, occupational, and SES levels were linked to a cluster of cardiovascular risk factors and a higher Framingham risk score. In most cases, social factors have a significant impact [23].
CVD diagnosis and under-reporting are more common among the poor in India. Because medical care usually involves significant out-of-pocket expenditures, economically disadvantaged CVD patients are less likely to get evidence-based therapy. Those in the low-income category face higher out-of-pocket expenditures than those in the high-income group, with higher rates of catastrophic health spending and financing for suffering [24]. As a result, households with lower SES that are affected by CVD are more likely to face financial hardship or catastrophic health costs. Out-of-pocket expenditures are not just a feature of acute care, but they are also present in chronic care. For example, diabetes treatment costs 34% (27%) of a low-income family's yearly income in urban (rural) India. As a result, poor and marginalized populations are pushed deeper into the poverty and CVD cycle [25].
1.3. Potential Risk Factors for CVD
Over the years, the main risk factors for these disorders have been identified as high levels of low-density lipoprotein (LDL) cholesterol, smoking, hypertension, diabetes, abdominal obesity, psychosocial factors, inadequate intake of fruits and vegetables, excessive alcohol consumption, and lack of adequate physical activity (Fig. 1). Diabetes mellitus is a documented epidemiological factor linked to the rising prevalence of CVD. Atherosclerosis, which is predominantly seen in the intima of medium and wide arteries, is the leading cause of myocardial infarction, heart failure, and stroke. Dyslipidemia in the vascular endothelium and cholesterol deposition is the major causes of atherosclerosis. When oxidized, low density lipoprotein (LDL) cholesterol is pro-inflammatory and immunogenic, and it acts as a standalone CVD risk factor [26]. The increase in oxidized LDL cholesterol adds to endothelial dysfunction and has a direct impact on the progression of atherosclerosis. Although more research is being conducted to better identify a person's cardiovascular risk in terms of genetic factors, more nuanced lipid traits, and inflammatory markers, the INTERHEART study confirmed that traditional risk factors accounted for over 90% of the population's risk of myocardial infarction [27].
Fig. (1)) Risk factors for cardiovascular diseases.1.4. Therapies in Use for CVD Treatment
1.4.1. ACE Inhibitors
ACE inhibitors are medicines that expand, or dilate your blood arteries to increase the quantity of blood your heart pumps and reduce your blood pressure. ACE inhibitors also improve blood flow, which helps your heart work less and protects your kidneys from the consequences of hypertension and diabetes [28]. Medications include trandolapril, ramipril, benazepril and captopril.
• Mechanism of Action of Trandolapril: The glycoprotein ACE inhibitor is made up of a single polypeptide chain of 1277 amino acids with two functionally active domains, N and C, that result from tandem gene duplication. Despite their considerable sequence similarity, the two domains have different physiological functions. The C-domain is primarily engaged in blood pressure control, whereas the N-domain is important in stem cell differentiation and proliferation. ACE inhibitors bind to both domains and reduce their function, but the C-domain has a far higher affinity and inhibitory effect.Trandolaprilat, a metabolite of trandolapril, competes with ATI for ACE binding and inhibits ATI enzymatic proteolysis to ATII. By blocking the pressor effects of ATII, lowering ATII levels in the body lowers blood pressure [29].
1.4.2. Angiotension II Receptor Blockers
Angiotensin-converting enzyme inhibitors (ARBs) inhibit the activity of the hormone angiotensin II. This hormone causes blood vessels to constrict, causing blood pressure to rise. Angiotensin II also causes the body to retain salt and water, which raises blood pressure even further. ARBs operate by inhibiting the hormone's receptors, particularly AT1 receptors located in the heart, blood vessels, and kidneys. Blocking the activity of angiotensin II lowers blood pressure and protects the heart and kidneys from harm. These medicines help reduce substances that induce the accumulation of salt and fluid in the body [30]. Medications include candesartan, irbesartan, losartan, telmisartan.
• Mechanism of Action of Candesartan: Candesartan inhibits angiotensin II binding to AT1 in a variety of tissues, including vascular smooth muscle and the adrenal glands. Angiotensin II's vasoconstrictive and aldosterone-secreting actions are inhibited by AT1, resulting in a reduction in blood pressure [31].
1.4.3. Antiarrhythmics
Antiarrhythmic medication therapy's ultimate objective is to restore normal rhythm and conduction. Antiarrhythmic medications are used to modify the excitability of cardiac cells by altering the duration of the effective refractory period, and inhibit aberrant automaticity [32].
Antiarrhythmic medicines are split into four categories:
Class I: Sodium-channel blockers, which slow electrical conduction in the heart [33]. Medicines include Quinidine, Procainamide, Disopyramide and Ajmaline.
• Mechanism of Action of Procainamide: Procainamide is a drug used to make local or regional anesthetic and to treat ventricular tachycardia that can develop during cardiac procedures like surgery or catheterization, as well as after acute myocardial infarction, digitalis poisoning, or other cardiac conditions [34]. It is a sodium channel blocker that acts as a local anaesthetic by blocking the ionic fluxes necessary for the initiation and conduction of impulses, stabilizing the neuronal membrane.
Class II: Beta-blockers, can reduce excessive blood pressure and heart rate by inhibiting impulses that may induce an irregular heart rhythm and interfering with hormonal effects (such as adrenaline) on the heart's cells [35]. Medicines include Lidocaine, Mexiletine and Phenytoin.
• Mechanism of Action of Lidocaine: The main impact that lidocaine has when it binds and blocks sodium channels, reducing the ionic fluxes essential for the initiation and conduction of electrical action potential impulses necessary for muscle contraction, is believed to be related with cardiac consequences. Lidocaine has substantial effects on the central nervous system and cardiovascular system in addition to inhibiting conduction in nerve axons in the peripheral nervous system.Lidocaine may generate stimulation of the CNS followed by depression after absorption, and it works predominantly on the myocardium in the cardiovascular system, causing reductions in electrical excitability, conduction rate, and force of contraction [36].
Class III: Potassium channel blockers, By inhibiting potassium channels in the heart, it slows electrical impulses in the heart. Amiodarone, Dronedarone, Sotalol, and Bretylium are some of the medications available.
• Mechanism of Action of Amiodarone: It is classified as an anti-arrhythmic medication of class III. It prevents the heart muscle from repolarizing during the third phase of the cardiac action potential by blocking potassium currents. As a result, amiodarone prolongs the action potential and increases the effective refractory period of cardiac cells (myocytes). As a result, the excitability of cardiac muscle cells is decreased, avoiding and treating aberrant heart rhythms [37].
Class IV: Calcium channel blockers, It binds to calcium channels found in vascular smooth muscle, cardiac myocytes, and cardiac nodal tissue (L-type calcium channels) (sinoatrial and atrioventricular nodes). These channels are in charge of controlling calcium input into muscle cells, which drives smooth muscle contraction and cardiac myocyte contraction [38]. Medicines include amlodipine, felodipine, nifedipine, nimodipine, nitrendipine.
• Mechanism of Action of Amlodipine: Amlodipine is a calcium antagonist (calcium ion antagonist or slow-channel blocker) that prevents calcium ions from entering vascular smooth muscle and cardiac muscle. The transport of extracellular calcium ions into cardiac muscle and vascular smooth muscle by particular ion channels is required for contraction. Amlodipine selectively inhibits calcium ion influx across cell membranes. Amlodipine has a larger effect on vascular smooth muscle cells than it does on cardiac muscle cells Label. Amlodipine reduces blood pressure by acting directly on vascular smooth muscle [39].
1.4.4. Antiplatelet Drugs
Platelets, by virtue of their ability to cling to the damaged blood vessel wall and attract new platelets to the site of injury, are essential components of normal hemostasis and crucial actors in atherothrombosis. Although platelet adhesion, activation, and aggregation can be viewed as a physiologic repair response to an atherosclerotic plaque's sudden fissuring or rupture, uncontrolled progression of such a process through a series of self-sustaining amplification loops can result in intraluminal thrombus formation, vascular occlusion, and subsequent ischemia or infarction [40]. Aspirin is the most widely studied antiplatelet drug.
• Mechanism of Action of Aspirin:This medication also prevents blood clots, strokes, and myocardial infarction by inhibiting platelet aggregation (MI). Acetylsalicylic acid (ASA) inhibits the production of prostaglandins. It doesn't discriminate between COX-1 and COX-2 enzymes. Platelet aggregation is inhibited for around 7-10 days when COX-1 is inhibited (average platelet lifespan). Acetylsalicylic acid's acetyl group binds to a serine residue in the cyclooxygenase-1 (COX-1) enzyme, causing permanent inhibition. This stops pain-inducing prostaglandins from being produced [41].
1.4.5. M. Anti-coagulants Drugs
Clot buster medicines, also known as thrombolytic treatment, are a type of cardiac medication used intravenously in the hospital to dissolve blood clots. Clot busters are most commonly used to treat heart attacks and ischemic strokes.
These strong heart disease medicines are used to stop heart attacks from becoming worse, stop ischemic stroke from getting worse, and break up blood clots in other parts of the body [42]. Medication include Tenecteplase, Urokinase, Streptokinase and Reteplase
• Mechanism of Action of Urokinase: It is a serine protease; cleaves plasminogen to form the active fibrinolytic protease, plasmin [41].
1.4.6. Diuretics
These are sometimes referred to as “water pills.” They assist your body in eliminating excess water and salt through urine. Your heart will have an easier time pumping as a result of this. It also aids in blood pressure management [43]. Medication includes Lasix, Bumex and Esidrix.
• Mechanism of Action of Lasix: Furosemide has direct vasodilatory actions, which explains why it is particularly successful in treating acute pulmonary edema. Vasodilation causes a decrease in the response to vasoconstrictors such angiotensin II and noradrenaline, as well as a decrease in the synthesis of endogenous natriuretic hormones having vasoconstricting characteristics. Increased synthesis of prostaglandins with vasodilating characteristics is also a result. In resistant arteries, furosemide may also open potassium channels [43].
There is strong evidence that pharmacological treatment can reduce cardiovascular events when conventional risk factors are taken into account. Several large clinical trials using HMG CoA reductase inhibitors (statins) have demonstrated that lowering LDL cholesterol with medicines lowers the risk of coronary and cerebrovascular events [44]. A reduction in high density lipoprotein (HDL) cholesterol raises the risk of atherosclerosis, whereas an increase in HDL cholesterol lowers the risk of coronary heart disease (CHD) and cardiovascular disease (CVD). Maintaining the quantity of HDL cholesterol can also induce the release of nitric oxide, which inhibits vascular bed atherogenesis [45]. Because atherosclerosis lesions take a long time to form, beginning cholesterol control early can help prevent atherosclerotic vascular disorders. Alternative therapies for lipid levels in individuals with dyslipidemia have been developed in recent years [46]. In addition to pharmacological therapy of CVD risk and the use of antithrombotic medicines, lifestyle changes are advised as a preventative strategy for controlling cardiovascular risk. The importance of dietary variables and herbal medications in the prevention and treatment of CVD is becoming more wellrecognized. Natural foods derived from medicinal plants have been shown to be beneficial to certain patients. More study, including clinical studies with extended follow-up data, is needed to determine their effectiveness against CVD disorders [47].
2. NUTRACEUTICALS AND CARDIOVASCULAR HEALTH
2.1. Nutraceuticals
CVDs are caused by a variety of interconnected variables, including age, poor eating habits, a sedentary and unhealthy lifestyle, and excessive job stress. In today's world, the traditional high fiber and carbohydrate diet has given way to a processed and packaged total fat diet. The term “nutraceutical” was coined by Dr. Stephen DeFelice in 1989, when he combined the words “nutrition” and “pharmaceutical.” According to DeFelice, a nutraceutical is “a food or portion of a food that delivers medical and health advantages, including the prevention and/or treatment of disease.” Isolated nutrient diets, herbal products, and genetically engineered designer meals are all examples of nutraceutical goods. “Let food be your medicine, and medicine be your nourishment,” Hippocrates said over 2500 years ago. The goal of human nutrition science has shifted from preventing nutritional insufficiency to preserving human health and lowering the risk of chronic illnesses [48]. Historically, food products have been designed with the consumer's flavor, appearance, value, and convenience in mind. The creation of items to prove health advantages is a relatively new trend, reflecting the growing understanding of the importance of nutrition in illness prevention and treatment. Japan presently has eleven different categories of functional ingredients or nutraceuticals as part of FOSHU (Foods for Specified Health Use). ß Fibres in the diet ß Oligosaccharides Cardiovascular diseases are illnesses that primarily affect the heart or blood vessels (CVDs) [49].
2.2. Potential Nutraceuticals
Nutraceuticals have been proven to be helpful in the prevention and risk control of CVDs, and can be broadly described as those utilized in the prevention or treatment of congestive heart failure, arrhythmias, hypertension, angina, and hyperlipidemia. The following section discusses a variety of nutraceuticals that have been proven to be effective in the prevention and treatment of cardiovascular disease [50]. Consumer demand has risen as a result of the link between the nutritional value of food ingredients and the prevention of a number of chronic illnesses. However, in order to stay on the market, these foods must be nutritional, organic, and delicious. They may be made up of a single physiologically active molecule or may require the inclusion of additional dietary components such as omega fatty acids, prebiotics, phytochemicals, and bioactive peptides in order to be consumed [51] (Fig. 2).
Fig. (2)) Effect on nutraceuticals on cardiovascular health.2.2.1. Plant Sterols/ Stanols
Plant sterols, also known as phytosterols, are naturally found in a range of plant sources, including vegetable oils, nuts, cereals, seeds, wood pulp, and leaves. Because they are physically similar to cholesterol, they compete with ingested cholesterol for absorption into the small intestine. This reduction in cholesterol absorption boosts LDL hepatic uptake and lowers LDL levels in the blood. Plant sterols have been demonstrated in studies to lower LDL cholesterol by 8-15%. Plant sterols are used to make natural grains like corn, maize, and sunflower. Studies have shown that plant sterols can reduce the risk of coronary heart disease [52].
2.2.2. Cruciferous Vegetables
DIM (3,3'-diin dolyl methane) and I3C (indole-3 carbinol) phytochemicals found in broccoli and kale suppress cytokine production and protect against inflammation, causing cell cycle arrest and death. Broccoli protects the myocardium from ischemia reperfusion injury through sulforaphane redox signaling. Upregulation of phase II detoxification enzymes involved in the clearance of reactive oxygen species (ROS). Sulforaphane is an anti-inflammatory agent. The antioxidant effects of phenolic substances, such as Brassica vegetables, are dependent on the amount and position of hydroxyl groups in the molecule. Quercetin, an important flavonol, inhibits cancer by chelating transition metal ions and trapping free radicals [53].
2.2.3. Garlic
As a source of flavonoids, garlic (Allium sativum) lowers the risk of hypertension and ischemic heart disease [54]. It also reduces the formation of plaque. It alters the platelet membrane's composition while also preventing superoxide leakage. It also reduces atheromatous deposition on the deepest layer of artery walls. Garlic extracts also have antihypertensive and anti-apoptotic properties [55]. Its ACE-inhibiting action also lowers blood pressure [56].
2.2.4. CoQ10
CoQ10 is an endogenous molecule, antioxidant, and free radical scavenger that functions as an electron transporter in the mitochondrial production of ATP. As a vascular superoxide antagonist, it lowers blood pressure, raises ventricular ejection fraction, and lowers arrhythmias. CoQ10 also improves mitochondrial energy generation, reduces peroxynitrite inactivation by NO, and reduces oxidative damage to LDL. In cardiac illness, there is a shortage of CoQ10. CoQ10 is found in the highest levels in meat, fish, and nuts, with considerably lower amounts in dairy products and fruits and vegetables. CoQ10 can help improve the ejection fraction in people with congestive heart failure [57].
2.2.5. Turmeric
Curcumin, an active component of turmeric, a tropical plant in the ginger family, is a polyphenolic antioxidant that reduces intracellular ROS. The primary ingredient is anti-inflammatory, and it also lowers LDL, triglycerides, and lipid peroxides. It inhibits hypertrophy and alters gene expression in cardiomyocytes. It suppresses nuclear acetylation and avoids the development of HF in hypertensive heart disease. Curcumin also suppresses platelet-derived growth factor (PDGF), which is necessary for vascular remodeling. Curcumin also causes epigenetic changes, which affect miRNAs, through food [58].
2.2.6. Grape Skin
Grape seed proanthocyanidin extract (GSPE) is a cardioprotective and antioxidant that helps to prevent cardiovascular disease. GSPE reduces infarct size and improves ventricular postischemic function. The oxidation of polyunsaturated LDL damages the arteries, resulting in atherosclerosis. Grape extracts prevent LDL from being oxidized. The efficacy of the GSPE material is dependent on the region of origin, as there is a wide range, and some estimations suggest that red wine is 20 times more active than white wine. The nuclear factor-kappa, which is implicated in the development of atherosclerotic plaques, is not activated by red
